Kwality Pharmaceuticals LtdNSE:KPL
Current view Q4 2026
Exports generic medicines. Sales jumped 36% to Rs503 crore as it pushes into higher-margin regulated European markets - but profit isn't turning into cash (only Rs17 crore collected) and money owed by customers is piling up.
Latest exchange filings last 5 · 5 after Q4 2026
- 2 Sep ’26AGM approved Swanith Kapoor as independent director and Aditya Arora’s 5-year reappointment from 30 Sept 2026. ↗
- 2 Sep ’26Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 2 Sep ↗
- 31 Aug ’26Kwality Pharmaceuticals held its 43rd AGM on August 31, 2026, approving six resolutions including director reappointments. ↗
- 13 Aug ’26Newspaper Publication of Unaudited Financial Results for the quarter ended June 30, 2026. ↗
- 12 Aug ’26Newspaper Publication of Notice of 43rd Annual General Meeting. ↗
Exchange filings, with the company's own one-line summary, read off the same page as the figures. Screener publishes only the most recent few, so this is the last 5 — not everything filed since your note, and a quiet-looking list is not proof of a quiet quarter. A filing is marked new when it is dated after the end of the quarter your note covers. Not scored, and not a judgement — a routine repayment notice and a takeover sit in the same list.
AI concall report · Q4 2026
The full earnings-call read behind this view — what management promised, what they delivered, and the earning trigger.
Growth Q4 2026
| Metric | This year vs lastYoY · vs Q4 2025 | vs the quarter beforeQoQ, sequential · vs Q3 2026 | 3-year yearly average3Y CAGR · compounded | 5-year yearly average5Y CAGR · compounded |
|---|---|---|---|---|
| Sales | ▲ +35.3% | +27.6% | +26.1% | +13.9% |
| Operating profit | ▲ +50.0% | +30.0% | +36.7% | +31.1% |
| EPS | ▲ +74.6% | +58.0% | +51.5% | +34.8% |
| PAT | ▲ +78.6% | +56.3% | — | — |
Tinted rows drive the Tier. Tier = the weaker of YoY Sales and YoY PAT growth. Here the weaker is Sales at +35.3%, which is ≥ 20% → Tier 1.
QoQ is sequential, not a trend. For most Indian companies the March quarter is seasonally the largest, so a June-quarter fall against it is a calendar effect. Only the YoY column feeds the Tier.
Multibagger potential
No score — no price history. The eight growth columns arrive with the quarter's Excel import; until then a number here would be invented.
How it compares with its rivals Healthcare · 6 of 159 listed
These are the industry's largest names rather than companies of its own size, so the columns are worth reading straight across — a ranking against them would only be restating the size gap.
| Company | Price | P/E | Size | ROCE | Profitlast qtr | Saleslast qtr |
|---|---|---|---|---|---|---|
| Kwality Pharma | ₹3,480 | 44.2× | ₹3,611 Cr | 24.1% | +114.8% | +45.6% |
| Sun Pharma.Inds. | ₹1,851 | 35.1× | ₹4.44 L Cr | 20.5% | +6.0% | +10.5% |
| Divi's Lab. | ₹9,379 | 83.5× | ₹2.49 L Cr | 22.0% | +65.5% | +27.8% |
| Torrent Pharma. | ₹4,858 | 82.8× | ₹1.85 L Cr | 15.2% | +5.8% | +54.9% |
| Zydus Lifesci. | ₹1,154 | 23.7× | ₹1.15 L Cr | 21.1% | −35.1% | +22.0% |
| Cipla | ₹1,374 | 31.0× | ₹1.11 L Cr | 15.5% | −39.2% | +2.3% |
Screener's own peer group, from the request already made for the industry P/E. It serves the industry's largest names by market cap, not companies of a similar size, so treat this as context rather than a like-for-like table; this company is always shown. On a phone the price, size and sales columns are dropped rather than pushed off the edge. Not part of the score.
Business quality to Jun 2026
| Are the margins widening? | yes — widening, and steadily | operating margin 20% → 25% over 3 years |
|---|---|---|
| Did the profit turn into cash? | most of it, with some tied up | 32% last year, 61% over three · free cash flow −₹29 cr, positive in 3 of 5 years |
| Is the growth borrowed? | lightly borrowed | ₹130 cr — 0.39× its own equity (was 0.42×) |
| Is it being collected? | customers are taking longer to pay | 203 days to collect, up 51 in a year · cash cycle 170 days |
| Who has been buying? | the promoters have held steady | promoters 54.9%, 54.8% → 54.9% over 2.8 years · FIIs 3.1% (+3.1) · DIIs 0.6% (+0.2) · shareholders 6,291 → 13,279 |
| What does it earn on its capital? | earns a high return on the capital it employs | ROCE 24.1% · ROE 22.6% |
Fetched from the filings, not typed — and deliberately not part of the score. These are the questions the score cannot ask: it reads growth, price and trend, so a company can score well while its profit never becomes cash. Weigh these beside the note, not against the number.
Screener's own checklist not mine, not the score
In its favour
- Company is expected to give good quarter
- Company has delivered good profit growth of 34.8% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 18.1%
- Company's median sales growth is 27.4% of last 10 years
Against it
- Stock is trading at 10.8 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 203 days.
Generated by screener.in from a fixed checklist — not written by me and not an input to the score. It is here as a second machine opinion to weigh against the note; where it disagrees with the view above, the note is the considered one.